AZTR Key Statistics, Chart & Performance
The current stock price of AZTR is 0.301 USD. In the past month the price decreased by -15.66%. In the past year, price decreased by -90.28%.
AZTR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.34 | 406.46B | ||
| AMGN | AMGEN INC | 15.22 | 179.28B | ||
| GILD | GILEAD SCIENCES INC | 15.23 | 154.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.66 | 117.45B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.44 | 82.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 785.47 | 52.92B | ||
| INSM | INSMED INC | N/A | 37.94B | ||
| NTRA | NATERA INC | N/A | 32.26B | ||
| BIIB | BIOGEN INC | 10.58 | 25.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.22 | 21.84B | ||
| INCY | INCYTE CORP | 15.59 | 19.65B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About AZTR
Company Profile
Azitra, Inc. is an early-stage clinical biopharmaceutical company, which engages in the development of therapeutic use in dermatology. The company is headquartered in Branford, Connecticut and currently employs 12 full-time employees. The company went IPO on 2023-06-16. The firm is focused on developing advanced therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. The company has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen its library of strains for drug-like molecules. Its lead product, ATR-12, is a genetically modified strain of S. epidermidis for treating the orphan disease, Netherton syndrome, a chronic and fatal disease of the skin. Its advanced product, ATR-04, is a genetically modified strain of S. epidermidis for treating papulopustular rash. Its product ATR-01 is a human filaggrin protein for treating ichthyosis vulgaris, a chronic, xerotic (abnormally dry), and scaly skin disease.
Company Info
AZITRA INC
21 Business Park Drive, Suite 6
Branford CONNECTICUT US
Employees: 12
Phone: 12034890183
AZITRA INC / AZTR FAQ
What does AZITRA INC do?
Azitra, Inc. is an early-stage clinical biopharmaceutical company, which engages in the development of therapeutic use in dermatology. The company is headquartered in Branford, Connecticut and currently employs 12 full-time employees. The company went IPO on 2023-06-16. The firm is focused on developing advanced therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. The company has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen its library of strains for drug-like molecules. Its lead product, ATR-12, is a genetically modified strain of S. epidermidis for treating the orphan disease, Netherton syndrome, a chronic and fatal disease of the skin. Its advanced product, ATR-04, is a genetically modified strain of S. epidermidis for treating papulopustular rash. Its product ATR-01 is a human filaggrin protein for treating ichthyosis vulgaris, a chronic, xerotic (abnormally dry), and scaly skin disease.
Can you provide the latest stock price for AZITRA INC?
The current stock price of AZTR is 0.301 USD. The price decreased by -4.02% in the last trading session.
What is the dividend status of AZITRA INC?
AZTR does not pay a dividend.
What is the ChartMill rating of AZITRA INC stock?
AZTR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
How is the valuation of AZITRA INC (AZTR) based on its PE ratio?
AZITRA INC (AZTR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-15.78).
Would investing in AZITRA INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on AZTR.
Is AZITRA INC (AZTR) expected to grow?
The Revenue of AZITRA INC (AZTR) is expected to decline by -100% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
AZTR Technical Analysis
AZTR Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to AZTR. AZTR may be in some trouble as it scores bad on both profitability and health.
AZTR Financial Highlights
Over the last trailing twelve months AZTR reported a non-GAAP Earnings per Share(EPS) of -15.78. The EPS decreased by -29.82% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -226.68% | ||
| ROE | -402.31% | ||
| Debt/Equity | 0 |
AZTR Forecast & Estimates
7 analysts have analysed AZTR and the average price target is 2.75 USD. This implies a price increase of 814.95% is expected in the next year compared to the current price of 0.301.
For the next year, analysts expect an EPS growth of 75.83% and a revenue growth -100% for AZTR